Install
Pharmaphorum is an online publication on a mission to educate, inform, engage, and connect pharmaceutical industry leaders and to equip them to thrive in healthcare’s evolving digital future. Pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in
- 1,023articles · 365d
- 2+ day agolatest article
- Sep 15, 2025earliest in window
- 70%with images
- 363avg words
- Medical 785
- Health & Wellness 694
- Health 508
- Economy, Business & Finance 336
- Business & Industrial 281
- Finance & Business 154
- Science & Technology 143
- Science & Nature 61
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Bayer moves Hyrnuo into frontline lung cancer treatment
2+ day, 18+ hour ago (562+ words) Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), just a year after it was cleared as a second-line option. Hyrnuo (sevabertinib) has been cleared for earlier use…...
FDA starts review of AZ's COPD blockbuster hope
3+ day, 18+ hour ago (616+ words) The FDA has started a priority review of AstraZeneca's IL-33-targeting antibody tozorakimab for chronic obstructive pulmonary disease (COPD), setting up a decision on the would-be blockbuster in the first quarter of 2027. It's an indicator of AZ's excitement about tozorakimab that…...
Pharvaris plans filings for HAE drug after pivotal trial win
4+ day, 16+ hour ago (552+ words) Swiss biotech Pharvaris has reported positive data from a phase 3 trial of its drug for hereditary angioedema (HAE), setting up marketing applications next year. The drug – an extended-release formulation of bradykinin B2 receptor antagonist deucrictibant – achieved an 83% reduction compared to placebo…...
AI in clinical trials: Building better trials before they start
4+ day, 19+ hour ago (809+ words) Drug development is an inherently risky endeavour, with the average probability of approval for a drug entering Phase I studies now sitting at just 6.7%. While much of this can be attributed to lack of efficacy, factors such as poor clinical…...
10th Dermatology Drug Development Summit
5+ day, 15+ hour ago (159+ words) The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease. The meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets,…...
FDA overrides adcomm and approves AZ's oral SERD
5+ day, 19+ hour ago (526+ words) The FDA has gone against the advice of its own expert advisors and approved AstraZeneca's Etcamah as a frontline treatment for breast cancer. Oral selective oestrogen receptor degrader (SERD) Etcamah (camizestrant) has been cleared in the US for use in…...
US puts $125m into personalised RNA therapy production
1+ week, 3+ day ago (539+ words) The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, to build a network for producing 'made-to-order' RNA-based genetic medicines. The Genetic Medicines and Individualised Manufacturing for Everyone (GIVE) programme will replace…...
Decarbonising respiratory care requires a new kind of generics innovation
1+ week, 4+ day ago (422+ words) Generics manufacturers have long played a critical role in supporting the sustainability of the NHS, delivering affordable medicines at scale, expanding patient access, and helping healthcare systems manage increasing demand under growing financial pressure. But as the NHS accelerates towards…...
FDA clears Takeda, Protagonist's first-in-class PV drug
1+ week, 5+ day ago (540+ words) Takeda and Protagonist Therapeutics' hepcidin mimetic rusfertide has been approved by the FDA to treat polycythaemia vera (PV), offering a new type of therapy for patients living with the rare blood disorder. The first-in-class drug has been cleared under the…...
FDA greenlights Regeneron drug for rare bone disease
3+ week, 3+ day ago (365+ words) The FDA has officially granted approval for Regeron's garetosmab-grts, to be sold under the brand name Pasatru. A monoclonal anitbody that blocks the protein Activin A, Pasatru is the second treatment to be approved for the ultra-rare disease fibrodysplasia ossificans…...